drugset

drugset / Trial / NCT01218594

Curative Effect Study of Endostatin Combined With Chemoradiotherapy to Non-small-cell Lung Cancer

NCT01218594 ↗

Phase 2 Unknown 50 enrolled Sun Yat-sen University Affiliated Hospital of Guangdong Medical University · collab Fifth Affiliated Hospital, Sun Yat-Sen University · collab Fujian Province Tumor Hospital · collab Guangzhou General Hospital of Guangzhou Military Command · collab The 458 Hospital of Chinese PLA · collab The Affiliated Tumor Hospital of Guangxi Medical University · collab Zhejiang Cancer Hospital · collab

NaSingle-groupOpen-labelTreatment

Summary

To evaluate the efficacy and safety of Endostar combined with concurrent chemo-radiotherapy (CCRT) in patients with unresectable stage III non-small-cell lung cancer (NSCLC).

Timeline

Start: 2009-05
Primary completion: 2013-12
Completion: 2015-12

Publications

Bao Y, Peng F, Zhou QC, Yu ZH, Li JC, Cheng ZB, Chen L, Hu X, Chen YY, Wang J, Wang Y, Ma HL, Xu ZM, Lu RB, Deng XW, Chen M. Phase II trial of recombinant human endostatin in combination with concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancer. Radiother Oncol. 2015 Feb;114(2):161-6. doi: 10.1016/j.radonc.2014.11.039. Epub 2014 Dec 9.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Endostar	Protein / enzyme biologic	7.5 mg/m2	Intravenous

Indications